AB Science : Les résultats du masitinib dans la SLA seront présentés à l’AAN 2023, et incluent l’analyse de la survie à long terme et une nouvelle analyse concernant la population de patients sans perte fonctionnelle à l'inclusion
12 avr. 2023 12h23 HE
|
AB Science
COMMUNIQUE DE PRESSE LES RÉSULTATS DU MASITINIB DANS LA SLA ONT ÉTÉ SÉLECTIONNÉS POUR UNE PRÉSENTATION SCIENTIFIQUE À LA RÉUNION ANNUELLE 2023 DE L'AMERICAN ACADEMY OF NEUROLOGY, ET INCLUENT...
AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline
12 avr. 2023 12h23 HE
|
AB Science
PRESS RELEASE RESULTS OF MASITINIB IN ALS SELECTED FOR A SCIENTIFIC PLATFORM PRESENTATION AT THE AMERICAN ACADEMY OF NEUROLOGY 2023 ANNUAL MEETING, INCLUDING LONG-TERM SURVIVAL...
Praxis Precision Medicines to Present Data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology Annual Meeting
01 avr. 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Updated Interim Data from Clene Nanomedicine’s RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting
01 avr. 2022 07h00 HE
|
Clene, Inc.
SALT LAKE CITY, April 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of Migraine
24 sept. 2020 06h00 HE
|
Axsome Therapeutics, Inc.
Significantly faster time to pain relief as compared to rizatriptan (p<0.001) Significantly less relapse of migraine pain as compared to rizatriptan (p=0.001) Benefits demonstrated in...
Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured Presentation
17 sept. 2020 07h00 HE
|
Axsome Therapeutics, Inc.
Data from MOMENTUM Phase 3 trial to be presented at the 2020 AAN Science Highlights Platform NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aaron's Inc. (AAN)
27 avr. 2020 18h29 HE
|
The Law Offices of Frank R. Cruz
LOS ANGELES, April 27, 2020 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors of the upcoming April 28, 2020 deadline to file a lead plaintiff motion in the class action filed...
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of Aaron's, Inc. (AAN)
21 avr. 2020 11h30 HE
|
Glancy Prongay & Murray LLP
LOS ANGELES, April 21, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 28, 2020 deadline to file a lead plaintiff motion in the class action...
DEADLINE ALERT for AAN, MGPI, ALGN, CAN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
17 avr. 2020 11h00 HE
|
Law Offices of Howard G. Smith
BENSALEM, Pa., April 17, 2020 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
DEADLINE ALERT for AAN, MGPI, ALGN, CAN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
10 avr. 2020 13h00 HE
|
Law Offices of Howard G. Smith
BENSALEM, Pa., April 10, 2020 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...